Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®

Autor: Cheng Y. Yang, Cottell Jeromy J, Krygowski Evan S, Jason K. Perry, Katana Ashley Anne, Mei Yu, Yujin Wang, Tran Chinh Viet, Guangyu Zhao, Yang Zheng-Yu, Kelly Wang, Yu-Jen Lee, Ruoyu Gong, Eric M. Gorman, Alejandra Trejo-Martin, Yang Tian, Kato Darryl, Erik Mogalian, Bacon Elizabeth M, Link John O, James G. Taylor, Guofeng Cheng, Zipfel Sheila
Rok vydání: 2019
Předmět:
Zdroj: Bioorganic & Medicinal Chemistry Letters. 29:2415-2427
ISSN: 0960-894X
Popis: Direct-acting antiviral inhibitors have revolutionized the treatment of hepatitis C virus (HCV) infected patients. Herein is described the discovery of velpatasvir (VEL, GS-5816), a potent pan-genotypic HCV NS5A inhibitor that is a component of the only approved pan-genotypic single-tablet regimens (STRs) for the cure of HCV infection. VEL combined with sofosbuvir (SOF) is Epclusa®, an STR with 98% cure-rates for genotype 1-6 HCV infected patients. Addition of the pan-genotypic HCV NS3/4A protease inhibitor voxilaprevir to SOF/VEL is the STR Vosevi®, which affords 97% cure-rates for genotype 1-6 HCV patients who have previously failed another treatment regimen.
Databáze: OpenAIRE